CSH guidelines for the diagnosis and treatment of drug-induced liver injury

  title={CSH guidelines for the diagnosis and treatment of drug-induced liver injury},
  author={Yue-Cheng Yu and Yi-Min Mao and Cheng-wei Chen and Jinjun Chen and Jun Chen and Wen-Ming Cong and Yang Ding and Zhong-Ping Duan and Qing-chun Fu and Xiaolei Guo and Peng Hu and Xi-qi Hu and Ji Dong Jia and Rongtao Lai and Dong-liang Li and Ying-Xia Liu and Lungen Lu and Shiwu Ma and Xiong Ma and Yue-min Nan and Hong Ren and Tao Shen and Hao Wang and Ji-yao Wang and Tai-ling Wang and Xiao‐jin Wang and Lai Wei and Qing Xie and Wen Xie and Chang-qing Yang and Dong-Liang Yang and Yanying Yu and Min-de Zeng and Li Zhang and Xin-Yan Zhao and Hui Zhuang},
  journal={Hepatology International},
  pages={221 - 241}
Drug-induced liver injury (DILI) is an important clinical problem, which has received more attention in recent decades. It can be induced by small chemical molecules, biological agents, traditional Chinese medicines (TCM), natural medicines (NM), health products (HP), and dietary supplements (DS). Idiosyncratic DILI is far more common than intrinsic DILI clinically and can be classified into hepatocellular injury, cholestatic injury, hepatocellular-cholestatic mixed injury, and vascular injury… 
Drug-induced liver injury
  • J. Suh
  • Medicine
    Yeungnam University journal of medicine
  • 2019
It is expected that the development of new therapies such as autophagy inducers and various other technologies of the fourth industrial revolution will be applicable to DILI research.
Drug-Induced Liver Injury: Highlights of the Recent Literature
While drug-induced hepatotoxicity remains a diagnosis of exclusion, the diverse array of publications that appeared in 2017 and 2018 provided important advances in understanding of DILI, paving the way for the improved ability to make a more definitive diagnosis and risk assessment.
Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines
This APASL consensus guidelines on D ILI is a concise account of the various aspects including current evidence-based information on DILI with special emphasis on DilI due to antituberculosis agents and traditional and complementary medicine use in Asia.
Drug-induced liver injury in cancer patients
The prevention and treatment regimens for DILI in patients receiving chemotherapy and immunotherapy various localizations of cancer given both in research and in practical recommendations are given.
Dissecting the molecular pathophysiology of drug-induced liver injury
The pathophysiological mechanisms underlying DILI are discussed and common forms of hepatocyte death and their association with the activation of specific signaling pathways are examined.
Translating new knowledge on drug-induced liver injury into clinical practice
Advances and results obtained by DILI registries around the world, case characterisations, particularly those relevant to newer definitions in DILi, and the behaviour of chronic liver disease induced by drugs will be updated.
Chronic Drug-Induced Liver Injury: Updates and Future Challenges
The definition of chronic DILI, updated clinical studies in terms of incidence, special manifestations, and promising risk factors, along with the recent progress and challenges in glucocorticoid therapy are reviewed.
Drug-induced Liver Injury Due to Lepidium meyenii (Maca) Medicinal Liquor
A case of liver injury that was probably directly induced by Maca is reported, suggesting that the safety of Maca should be evaluated by further studies.
Characteristics of Drug-Induced Liver Injury in Northeast China: Disease Spectrum and Drug Types
The aim of this study was to determine the disease spectrum and drug types causing drug-induced liver injury (DILI) in northeast China, so that the affected population can be reminded of the need to
Corticosteroid therapy in drug‐induced liver injury: Pros and cons
The history and current status of corticosteroid use in liver diseases and the pros and cons of cortICosteroid treatment in DILI are summarized, the DILi candidates who may benefit from corticosterone therapy, the administration route and dosage, and the adverse effects related to corticOSToid use are explored.


ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury
This ACG Clinical Guideline is presented an evidence-based approach to diagnosis and management of DILI with special emphasis on DILi due to herbal and dietary supplements and DilI occurring in individuals with underlying liver disease.
Drug-induced liver injury: Icelandic lessons.
The authors took advantage of the limited but well characterized population of Iceland and the excellent and centralized medical care system enjoyed by that population to estimate the incidence of drug-induced liver injury as 19 cases per 100,000 persons per year, somewhat higher than previous estimates.
Role of immune reactions in drug-induced liver injury (DILI)
A variety of hypotheses for the pathogenesis of DILI center around a pathogenic role of drug- (or drug-metabolite–) specific adaptive immune cells, as well as hepatic-injury–induced innate immune responses in the development, progression, and/or resolution of D ILI.
Clinical features, diagnosis, and natural history of drug-induced liver injury.
There are no objective tests to definitively diagnose DILI and the diagnosis depends on thorough and accurate history taking, follow-up of the patient's clinical course and excluding more common causes of liver injury.
Histological patterns in drug-induced liver disease
The diagnosis of drug-induced liver injury (DILI) is a challenging problem, often confounded by incomplete clinical information and the difficulty of eliciting exposure to herbal products,
Drug hepatotoxicity.
Drug-induced liver injury: a summary of recent advances
The new and updated DILI registries for 2010 are presented, including the latest information on the causes and outcomes of non-acetaminophen DILi cases in the US Acute Liver Failure Study Group database.
Idiosyncratic drug-induced liver injury: an update on the 2007 overview
An update on the epidemiology, pathogenic mechanisms, diagnosis, outcome, risk factors for idiosyncratic drug-induced hepatotoxicity, specific classes of drug hepatot toxicity and biomarkers to predict DILI are covered.
An update on drug induced liver injury.
Drug induced liver injury is an uncommon cause of acute and chronic liver injury of increasing importance to patients, clinicians, and regulators and recent studies have shown that statins are actually safe and efficacious to use in hyperlipidemic patients with chronic liver disease.